Catalent, Inc. (NYSE:CTLT) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC boosted its holdings in Catalent, Inc. (NYSE:CTLTFree Report) by 240.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,249 shares of the company’s stock after purchasing an additional 28,410 shares during the quarter. SG Americas Securities LLC’s holdings in Catalent were worth $1,808,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the business. Thompson Siegel & Walmsley LLC increased its stake in Catalent by 46.6% during the third quarter. Thompson Siegel & Walmsley LLC now owns 704,322 shares of the company’s stock worth $32,069,000 after acquiring an additional 223,944 shares during the last quarter. Vanguard Group Inc. increased its stake in Catalent by 1.8% during the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock worth $931,909,000 after acquiring an additional 365,648 shares during the last quarter. Hsbc Holdings PLC increased its stake in Catalent by 43.1% during the third quarter. Hsbc Holdings PLC now owns 193,322 shares of the company’s stock worth $8,803,000 after acquiring an additional 58,240 shares during the last quarter. Schroder Investment Management Group increased its stake in Catalent by 8.4% during the third quarter. Schroder Investment Management Group now owns 1,335,283 shares of the company’s stock worth $60,795,000 after acquiring an additional 103,241 shares during the last quarter. Finally, Barclays PLC increased its stake in Catalent by 41.7% during the third quarter. Barclays PLC now owns 4,797,718 shares of the company’s stock worth $218,440,000 after acquiring an additional 1,412,058 shares during the last quarter.

Catalent Trading Down 0.1 %

NYSE:CTLT opened at $56.44 on Friday. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34. The business’s 50 day moving average is $55.84 and its two-hundred day moving average is $47.20. Catalent, Inc. has a 52 week low of $31.45 and a 52 week high of $68.08. The company has a market cap of $10.20 billion, a PE ratio of -8.30, a P/E/G ratio of 3.56 and a beta of 1.20.

Catalent (NYSE:CTLTGet Free Report) last released its earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the business earned $0.62 EPS. The company’s quarterly revenue was down 10.2% on a year-over-year basis. On average, analysts predict that Catalent, Inc. will post 0.48 EPS for the current year.

Analyst Upgrades and Downgrades

CTLT has been the subject of a number of recent research reports. UBS Group reiterated a “neutral” rating and issued a $63.50 target price (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Barclays increased their target price on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. StockNews.com initiated coverage on Catalent in a research note on Tuesday. They issued a “sell” rating for the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, February 20th. Finally, Stephens reiterated an “equal weight” rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, February 6th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Catalent presently has a consensus rating of “Hold” and a consensus price target of $52.46.

Get Our Latest Analysis on Catalent

Catalent Profile

(Free Report)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

See Also

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLTFree Report).

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.